

CONTENTS

Title	Page No.
Certificate	iii
Declaration by the Candidate	iv
Copyright Transfer Certificate	v
Acknowledgments	vi
Contents	viii-xii
List of Figures	xiii-xvii
List of Schemes	xviii
List of Tables	xix-xx
List of Abbreviations	xxi-xxiii
PREFACE	xxiv-xxvi
CHAPTER 1: Introduction and Literature Review	01-53
1.1. Alzheimer's disease: A progressive neurodegenerative disease	01
1.2. Prevalence of AD	02
1.3. Pathophysiology of AD	03-12
1.3.1. Amyloid Cascade Hypothesis	04
1.3.2. Tau Hypothesis	06
1.3.3. Cholinergic Hypothesis	07
1.3.4. Metal ion hypothesis	08
1.3.5. Oxidative stress and Reactive oxygen species hypothesis	09
1.3.6. Inflammation Hypothesis	11
1.4. Current therapeutics for AD	12
1.5. Need of new and effective treatment for AD	16
1.6. Protein aggregation in AD	16
1.7. Mechanism of protein aggregation	17
1.8. A β aggregation inhibitors	19
1.9. Tau aggregation inhibitors	20
1.10. Computational modeling in Drug Design	23-28
1.10.1. Molecular docking	25
1.10.2. Molecular dynamics	25
1.10.3. Artificial Intelligence in drug discovery	26
1.10.4. Limitations and challenges of using computational modeling for drug discovery	27
1.11. α -Ketoamides	28-41
1.11.1. Chemistry of α -Ketoamides	28
1.11.2. Role of α -ketoamides in Neurodegenerative disease	31
1.11.3. Biological importance of α -Ketoamide based molecules in other disease	34
1.11.4. Methods of synthesis of α -ketoamides	37
1.12. References	41
CHAPTER 2: Research Envisaged	54-57
CHAPTER 3: Synthesis, single crystal X-ray, DFT, spectroscopic, molecular docking studies, and in vitro biological evaluation of compound N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide	58-104

	Title	Page No.
3.1.	Introduction	58
3.2.	Objectives	59
3.3.	Results and discussions	60-94
3.3.1.	Synthesis of N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide (Compound1)	60
3.3.2.	Description of crystal structure	61
3.3.3.	Hirshfeld Surface (HS) Analysis	63
3.3.4.	Energy Framework Calculations	67
3.3.5.	Optimization of the Geometry	69
3.3.6.	Vibrational Spectra Calculation	71
3.3.7.	Molecular Electrostatic Potential	73
3.3.8.	UV-Vis Spectroscopy	74
3.3.9.	HOMO-LUMO Analysis and Reactivity Descriptors	74
3.3.10.	Mulliken Population Analysis and Fukui Function	76
3.3.11.	NBO and NHO Analysis	77
3.3.12.	NMR Spectra	80
3.3.13.	In Vitro Biological evaluation	83
3.3.13.1	Effect of compound 1 on A β ₄₂ aggregation	83
3.3.13.2	In Vitro Cellular Toxicity Assay	84
3.3.14.	Molecular Docking Study	85
3.3.15.	Molecular Dynamics Simulation	86-94
3.4.	Materials and Methods	94-99
3.4.1.	Materials	94
3.4.2.	Instrumentation Details	94
3.4.3.	Synthesis of N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide (1)	94
3.4.4.	Single crystal X-Ray diffraction	95
3.4.5.	Computational details	96
3.4.6.	Molecular Dynamics simulation	97
3.4.7.	Biological evaluation details	97
3.5.	Conclusion	99
3.6.	Reference	100
	CHAPTER 4: Design, Synthesis, and Biological Evaluation of Halogen-Substituted Novel α-Ketoamides as Potential Protein Aggregation Modulators	105-169
4.1.	Introduction	105
4.2.	Objectives	106
4.3.	Results and Discussion	107-146
4.3.1.	Chemistry	107
4.3.2.	In vitro A β aggregation assay and Structure Activity Relationship study	108
4.3.3.	Solubility study of the hit compounds	113
4.3.4.	In Vitro Blood Brain Barrier Permeability study of the compound BD23	114
4.3.5.	Compound BD23 inhibited Heparin-Induced Tau Aggregation	115
4.3.6.	In Vitro Cytotoxicity Assay	115
4.3.7.	In vivo Behavioral Studies of compound BD23 in A β -induced	117

	Title	Page No.
	Cognitive Deficit Mice Model	
4.3.8.	In silico Molecular Docking Study	121
4.3.9.	In silico Quantum Chemical Studies	128
4.3.10.	Molecular Dynamics Simulation Study	129
4.3.11.	Free Energy Landscape (FEL) Analysis	142
4.3.12.	In Silico ADME	145
4.4.	Materials and Methods	147-165
4.4.1.	Chemistry	147
4.4.1.1.	General procedure for the synthesis of γ -Substituted β,γ -unsaturated α -keto thioesters (3a-c) and γ -Substituted β,γ -unsaturated α -hydroxy thioesters (4a-c)	147
4.4.1.2.	General procedure for the synthesis of β,γ -unsaturated α -ketoamides (BD01 to BD08)	148
4.4.1.3.	General procedure for the synthesis of β,γ -saturated α -ketoamides (BD09 to BD28)	150
4.4.2.	In Vitro Assay	158-161
4.4.2.1.	A β ₄₂ monomer preparation and ThT fluorescence assay	158
4.4.2.2.	Analysis of A β ₄₂ aggregation kinetics	159
4.4.2.3.	In vitro Heparin-Induced Tau Aggregation Assay	160
4.4.2.4.	In Vitro Cytotoxicity Assay	161
4.4.3.	In Vivo Behavioral Studies of Compound BD23 in A β -induced Cognitive Deficit Mice Model	161
4.4.3.1.	Experimental animals	161
4.4.3.2.	Drug Treatment	162
4.4.3.3.	Learning and Memory test	162
4.4.3.4.	Motor coordination	162
4.4.3.5.	Novel Object Recognition Test	163
4.4.4.	Solubility Determination	163
4.4.5.	PAMPA Assay	163
4.4.6.	Computational Details	164
4.4.6.1.	In silico Pharmacokinetic properties	164
4.4.6.2.	Molecular Docking	164
4.4.6.3.	Molecular Dynamics	165
4.4.6.4.	Quantum Chemical Calculations	165
4.5.	Conclusion	165
4.6.	References	166
	CHAPTER 5: Design, Synthesis, and Biological Evaluation of Indole and Piperazine-Substituted Ketoamides as Potential Protein Aggregation Modulators	170-222
5.1.	Introduction	170
5.2.	Objectives	172
5.3.	Results and Discussion	173
5.3.1.	Chemistry	173
5.3.2.	In vitro A β aggregation assay and Structure Activity Relationship study	175
5.3.3.	Solubility study of the Hit Compounds	178
5.3.4.	In Vitro Blood Brain Barrier Permeability Study of the compound	178

	Title	Page No.
	MD08	
5.3.5.	Compound MD08 inhibited Heparin-Induced Tau Aggregation	179
5.3.6.	In Vitro Cytotoxicity Assay	179
5.3.7.	In Vivo Behavioral Studies of Compound MD08 in A β -Induced Cognitive Deficit Mice Model	181
5.3.8.	In silico Molecular docking study	183
5.3.9.	In silico Quantum Chemical Studies	191
5.3.10.	Molecular Dynamics Simulation Study	193
5.3.11.	Free Energy Landscape (FEL) Analysis	206
5.3.12.	In Silico ADME	208
5.4.	Materials and Methods	210
5.4.1.	Chemistry	210
	5.4.1.1. General Procedure for the synthesis of compound MD01 to MD24	210
5.4.2.	In Vitro Biological Evaluation	219
	5.4.2.1. A β ₄₂ monomer preparation and ThT fluorescence assay	219
	5.4.2.2. Analysis of A β ₄₂ aggregation kinetics	219
	5.4.2.3. In vitro Heparin-Induced Tau Aggregation Assay	219
5.4.3.	In vivo study A β -induced memory impairment in mice	219
	5.4.3.1. Experimental animals	219
	5.4.3.2. Drug Treatment	219
	5.4.3.3. Learning and memory test	219
	5.4.3.4. Motor coordination	219
	5.4.3.5. Novel object recognition test	219
5.4.4.	Solubility Determination	219
5.4.5.	PAMPA Assay	219
5.4.6.	Computational Details	220
	5.4.6.1. In silico Pharmacokinetic properties	220
	5.4.6.2. Molecular Docking	220
	5.4.6.3. Molecular Dynamics	220
	5.4.6.4. Quantum Chemical Calculations	220
5.5.	Conclusion	220
5.6.	References	221
CHAPTER 6: Artificial Intelligence Assisted Identification of Potential Tau Aggregation Inhibitors		223-271
6.1.	Introduction	223
6.2.	Objective	223
6.3.	Results and discussion	224-259
	6.3.1. Artificial Intelligence Based Virtual Screening	225
	6.3.2. Replica Exchange Molecular Dynamics (REMD) simulation and clustering of tau structures	226
	6.3.3. Active site Identification	232
	6.3.4. Structure-Based Virtual screening	233
	6.3.5. In Silico ADME prediction	239
	6.3.6. Molecular Dynamics Simulation	242
	6.3.7. Binding Free Energy Calculation	257

	Title	Page No.
6.4.	Material and methods	259-265
6.4.1.	Artificial Intelligence Based Virtual Screening	259
6.4.2.	Screening database	260
6.4.3.	Diversity picking using RDKit Diversity picker	261
6.4.4.	REMD simulation	261
6.4.5.	Active site identification	262
6.4.6.	Molecular Docking	263
6.4.7.	In Silico ADME prediction	263
6.4.8.	Molecular Dynamics simulation	264
6.4.9.	Binding Free Energy Calculation	264
6.5.	Conclusion	265
6.6.	References	266
	CHAPTER 7: Summary & Conclusion	272-275
	Annexure I: List of NMR, HRMS, HPLC Data for Chapter 4	276-319
	Annexure II: List of NMR, HRMS, HPLC Data for Chapter 5	320-357
	Annexure III: List of Publication	358-359